(Hypertension. 1995;26:828.)
© 1995 American Heart Association, Inc.
Articles |
Attenuation of Genetic Hypertension After Short-term Vasopressin V1A Receptor Antagonism
From the University of Melbourne, Austin Hospital, Heidelberg, Victoria, Australia.
Correspondence to Dr Louise M. Burrell, Department of Medicine, University of Melbourne, Austin Hospital, Studley Road, Heidelberg 3084, Victoria, Australia.
Abstract Abnormalities of the vasopressin system are found in genetic hypertension. This study compares the delayed effects of a brief period of vasopressin V1A receptor blockade and angiotensin-converting enzyme inhibition in young female and male spontaneously hypertensive rats (SHR) on the development of hypertension in adult life. In a separate study, the role of vasopressin in the maintenance of blood pressure in adult SHR was assessed. Young SHR received either the nonpeptide vasopressin V1A receptor antagonist OPC-21268, the angiotensin-converting enzyme inhibitor ramipril, or vehicle from 6 to 10 weeks of age. During the treatment period, OPC-21268 and ramipril reduced systolic blood pressure compared with control SHR (P<.001). Blood pressure in male SHR 7 weeks after treatment withdrawal was 178±1 mm Hg in ramipril-treated, 184±1 mm Hg in OPC-21268–treated, and 200±2 mm Hg in control SHR (P<.001). Similar results were seen in female SHR, although both OPC-21268 and ramipril were less effective antihypertensive agents in female compared with male SHR. The sustained attenuation in blood pressure was not associated with significant cardiovascular structural changes (left ventricular–to–body weight ratio, renal weight–to–body weight ratio, mesenteric resistance artery media-to-lumen ratio). Results of vasopressin V1A receptor binding kinetics and plasma renin or aldosterone concentrations did not suggest a lasting effect of OPC-21268 on the vasopressin system or of ramipril on the renin-angiotensin system following treatment withdrawal. One week of OPC-21268 treatment in adult SHR had no effect on systolic blood pressure, indicating that vasopressin is not involved in the maintenance of blood pressure. In contrast, this study demonstrates the novel finding that brief vasopressin V1A blockade in young SHR attenuates the development of hypertension in adult SHR despite withdrawal of drug treatment. These results support a role for vasopressin in the development of hypertension.
Key Words: vasopressins • hypertension, genetic • receptors, vasopressin • angiotensin-converting enzyme inhibitors
This article has been cited by other articles:
 |
|
 |
|
  G. M. Pavan de Arruda Camargo, W. Abrao Saad, and L. A. de Arruda Camargo Vasopressin and angiotensin receptors of the medial septal area in the control of mean arterial pressure induced by vasopressin Journal of Renin-Angiotensin-Aldosterone System, September 1, 2008; 9(3): 133 - 138. [Abstract] [PDF]
|
|
|
|
 |
|
 T.-a. Koshimizu, Y. Nasa, A. Tanoue, R. Oikawa, Y. Kawahara, Y. Kiyono, T. Adachi, T. Tanaka, T. Kuwaki, T. Mori, et al. From the Cover: V1a vasopressin receptors maintain normal blood pressure by regulating circulating blood volume and baroreflex sensitivity PNAS, May 16, 2006; 103(20): 7807 - 7812. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 O. B. Vagnes, F. H. Hansen, J. J. Feng, B. M. Iversen, and W. J. Arendshorst Enhanced Ca2+ response to AVP in preglomerular vessels from rats with genetic hypertension during different hydration states Am J Physiol Renal Physiol, June 1, 2005; 288(6): F1249 - F1256. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
O. B. Vagnes, F. H. Hansen, R. E. F. Christiansen, C. Gjerstad, and B. M. Iversen Age-dependent regulation of vasopressin V1a receptors in preglomerular vessels from the spontaneously hypertensive rat Am J Physiol Renal Physiol, May 1, 2004; 286(5): F997 - F1003. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
O. Vagnes, J. J. Feng, B. M. Iversen, and W. J. Arendshorst Upregulation of V1 receptors in renal resistance vessels of rats developing genetic hypertension Am J Physiol Renal Physiol, June 1, 2000; 278(6): F940 - F948. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Thibonnier, A. Kilani, M. Rahman, T. P. DiBlasi, K. Warner, M. C. Smith, A. F. Leenhardt, and R. Brouard Effects of the Nonpeptide V1 Vasopressin Receptor Antagonist SR49059 in Hypertensive Patients Hypertension, December 1, 1999; 34(6): 1293 - 1300. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. Zicha and J. Kunes Ontogenetic Aspects of Hypertension Development: Analysis in the Rat Physiol Rev, October 1, 1999; 79(4): 1227 - 1282. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. B. Sampey, L. M. Burrell, and R. E. Widdop Vasopressin V2 receptor enhances gain of baroreflex in conscious spontaneously hypertensive rats Am J Physiol Regulatory Integrative Comp Physiol, March 1, 1999; 276(3): R872 - R879. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 L. M. Burrell, P. A. Phillips, J. Risvanis, R. K. Chan, K. L. Aldred, and C. I. Johnston Long-term effects of nonpeptide vasopressin V2 antagonist OPC-31260 in heart failure in the rat Am J Physiol Heart Circ Physiol, July 1, 1998; 275(1): H176 - H182. [Abstract] [Full Text] [PDF]
|
|